Edward Fox, MD, PhD
Clinical Associate Professor
Department of Neurology
University of Texas Dell Medical School
Austin, TX

Director, Multiple Sclerosis Clinic
Central Texas Neurology Consultants
Round Rock, TX

Lori Mayer, DNP, MSN, RN, MSCN
Director, Medical Research, MS Clinic of Central Texas
Central Texas Neurology Consultants
Round Rock, TX

Provided By

This activity is jointly provided by Postgraduate Institute for Medicine and CMEology


Activity Details

0.5 AMA PRA Category 1 Credits
0.5 Contact Hour(s)
Released: September 12, 2017
Expires: September 12, 2018
30 minutes to complete

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Physician Continuing Medical Education

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and CMEology. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

Postgraduate Institute for Medicine is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

This educational activity for 0.5 contact hours is provided by Postgraduate Institute for Medicine.

Activity Description

In this activity, experts in multiple sclerosis will discuss current views of the pathophysiology and immunopathogenesis of multiple sclerosis.

Statement of Educational Need

The increasing understanding of the immunopathogenesis of MS and the greater availability of disease-modifying therapies (DMTs) have shifted the aims of treatment. Modification of therapies is increasingly common in the context of growing knowledge of MS pathophysiology and DMT mechanisms of action. Education is needed to reformulate treatment strategies on the individual and systems levels.

Goals (Purpose) of Program

Healthcare providers who complete this activity should be able to effectively communicate and foster understanding of the disease process and the mechanism of action of DMTs with their patients.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Explain the role of B and T cells in MS pathophysiology
  • Identify mechanisms of action of current and emerging disease-modifying therapies in MS

Target Audience

This certified activity is designed to address the educational needs of neurologists, neurology advanced practice clinicians, and other healthcare providers who care for patients with multiple sclerosis.

Requirements for Successful Completion

Upon successfully completing the post-test with a score of 75% or better and the activity evaluation, the certificate will be made available immediately.


Internet activity

Conflict of Interest Policy/Disclosure Statement

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty have disclosed the following:
Edward Fox, MD, PhD
Consulting Fees:  Acorda Therapeutics, Bayer, Biogen, Inc., EMD Serono, Genentech, Genzyme, Novartis, Teva Pharmaceutical Industries, TG Therapeutics, Inc.; Contracted Research: Acorda Therapeutics, Biogen, Inc., Chugai Pharma USA, Inc., EMD Serono, Genentech, Novartis, Ono Pharma USA, Inc., Teva Pharmaceutical Industries, TG Therapeutics, Inc.

Lori Mayer, DNP, MSN, RN, MSCN
Consulting Fees (e.g. advisory boards):  Biogen, Inc., EMD Serono, Genentech, Novartis, Sanofi Genzyme; Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their Agents (e.g. speakers’ bureaus): Biogen, Inc., EMD Serono, Novartis, Sanofi Genzyme.

The following CMEology planners and managers, Rob Lowney, Dannielle McGuire, and Dana Ravyn, PhD, MPH, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/CE activity of any amount during the past 12 months.

The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN, and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/CE activity of any amount during the past 12 months.

Instructions for Receiving Credit

A brief post-test and course evaluation will follow the completion of the course. Please complete these questionnaires to claim credit for this course.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For questions about the accreditation of this activity, please contact Postgraduate Institute for Medicine at: (303) 799-1930 or

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Start Activity

Select your specialty

You must select a specialty

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.